Nesina

Physical Activity, Type 2 Diabetes, Diet

Treatment

4 FDA approvals

20 Active Studies for Nesina

What is Nesina

Alogliptin

The Generic name of this drug

Treatment Summary

Alogliptin is an oral medication that helps control blood sugar levels by inhibiting the activity of the enzyme dipeptidyl peptidase-4 (DPP-4). It is available as a benzoate salt and is mainly composed of the R-enantiomer. Alogliptin was approved by the FDA in 2013 and does not convert to the S-enantiomer when taken.

Nesina

is the brand name

image of different drug pills on a surface

Nesina Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nesina

Alogliptin

2013

26

Approved as Treatment by the FDA

Alogliptin, also known as Nesina, is approved by the FDA for 4 uses which include Type 2 Diabetes Mellitus and Physical Activity .

Type 2 Diabetes Mellitus

Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone

Physical Activity

Used to treat Exercise in combination with Pioglitazone

Type 2 Diabetes

Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone

Diet

Used to treat Diet in combination with Pioglitazone

Effectiveness

How Nesina Affects Patients

Alogliptin starts to reduce the levels of an enzyme (DPP-4) within 2-3 hours after being taken, and it continues to keep levels low for up to 24 hours with doses of 25 mg or higher. It also helps to lower glucagon and increase levels of a hormone (GLP-1) that helps regulate blood sugar levels. Taking alogliptin will not affect the time it takes for your heart to beat.

How Nesina works in the body

Alogliptin helps control blood sugar levels by blocking an enzyme called dipeptidyl peptidase 4 (DPP-4). This enzyme usually breaks down the hormones GIP and GLP-1, which stimulate insulin production. Alogliptin prevents this breakdown, so more of these hormones are in the blood. This increases insulin production, suppresses glucagon production, and helps with feelings of fullness.

When to interrupt dosage

The amount of Nesina is contingent upon the established affliction, including Diet, Physical Activity and Type 2 Diabetes. The dosage is subject to the mode of delivery (as outlined in the table below).

Condition

Dosage

Administration

Diet

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Type 2 Diabetes

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Physical Activity

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Nesina.

Common Nesina Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Alogliptin.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Alogliptin.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Alogliptin.

Clomipramine

Major

The metabolism of Clomipramine can be decreased when combined with Alogliptin.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Alogliptin.

Nesina Toxicity & Overdose Risk

Alogliptin overdose may lead to common side effects such as a sore throat, headache, and respiratory infection. These symptoms occur in at least 4% of those who take alogliptin and more often than in those taking a placebo.

Nesina Novel Uses: Which Conditions Have a Clinical Trial Featuring Nesina?

196 active studies are in progress to assess the potential of Nesina for improving Physical Activity, managing Type 2 Diabetes and providing Dietary benefits.

Condition

Clinical Trials

Trial Phases

Diet

4 Actively Recruiting

Not Applicable, Phase 1

Physical Activity

24 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Type 2 Diabetes

157 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Nesina Reviews: What are patients saying about Nesina?

5

Patient Review

11/11/2013

Nesina for Type 2 Diabetes Mellitus

This medication has been extremely effective for me. I take it along with a low dose of Amaryl each day, and my A1C level has dropped from 7.3 to 5.9 in just three months!

1

Patient Review

9/13/2016

Nesina for Type 2 Diabetes Mellitus

After taking Januvia for many years, my insurance company made me switch to Nesina. My blood sugar has been spiking since I started taking it, and I've already switched back to Januvia at my own expense.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nesina

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the medication Nesina used for?

"An injectable medication, Alogliptin is used to help manage blood sugar levels in people with type 2 diabetes. When combined with a proper diet and exercise regimen, this medication can help to prevent the onset of serious complications from diabetes, such as kidney damage, blindness, nerve problems, loss of limbs, and sexual dysfunction."

Answered by AI

Does Nesina have metformin in it?

"The drugs in Nesina Met are alogliptin and metformin hydrochloride. Alogliptin is given in a dose of 12.5 mg per 1000 mg metformin hydrochloride."

Answered by AI

What is the difference between Januvia and Nesina?

"If you're struggling to get your blood sugar under control, Januvia (sitagliptin) could be a good addition to your treatment plan. Januvia lowers blood sugar levels and is taken orally, so you don't have to worry about injections. Nesina (alogliptin) is another option for oral treatment, but it's not as effective as Januvia."

Answered by AI

Does Nesina cause weight gain?

"Nesina will not make you gain weight. It helps the body to produce more insulin when blood sugar is high, and also tells the liver to reduce sugar production."

Answered by AI

Clinical Trials for Nesina

Image of Centre EPIC in Montreal, Canada.

Maple Syrup for Endurance Cycling Performance

18 - 45
Male
Montreal, Canada

The goal of this clinical trial is to learn whether maple syrup can be used as a natural carbohydrate source to help trained male cyclists perform better during long-duration cycling. The study also aims to learn how different amounts of maple syrup affect energy use in the body, stomach comfort, and feelings of effort and fatigue. The main questions the study aims to answer are: * Does consuming more carbohydrate from maple syrup help participants finish a 20-kilometer cycling time trial faster? * How do different amounts of maple syrup change how the body uses carbohydrates and fats during long exercise? * Are higher amounts of maple syrup easy for participants to tolerate without stomach problems? Researchers will compare four drinks: 1. A placebo drink (a look-alike drink with no calories), 2. A drink that provides 60 grams of carbohydrate per hour, 3. A drink that provides 90 grams per hour, and 4. A drink that provides 120 grams per hour. They will compare these drinks to see whether higher carbohydrate amounts lead to better cycling performance and how each dose affects comfort and metabolism. Participants will: * Attend a screening visit that includes a health check and a glucose tolerance test. * Complete a fitness test to measure their aerobic capacity and practice the cycling tests used in the study. * Take part in four separate exercise sessions in random order. Each session includes: * Drinking one of the four study beverages during 2 hours of steady cycling, * Completing two short, all-out 6-second sprints during the ride, * Completing a 20-kilometer cycling time trial as fast as possible, * Reporting stomach symptoms and perceptions of effort, * Providing breath, blood, urine, and sweat samples so researchers can measure how their body uses fuel. All drinks will look, taste, and smell similar so participants cannot tell which one they are receiving. Meals before each session will be provided to keep conditions the same across visits. This study may help athletes and active people choose natural carbohydrate sources that support both performance and comfort during long endurance exercise. The findings may also guide future research on the use of maple syrup as a sports nutrition option.

Waitlist Available
Paid Trial

Centre EPIC

Jonathan Tremblay, PhD

Mitacs

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Previous studies in the investigator's group demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Preliminary studies by the investigators in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. The investigators propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
Dietary Supplement

Faculty of Health Sciences

Have you considered Nesina clinical trials?

We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.
Go to Trials
Image of Central Research Associates - Flourish - PPDS in Birmingham, United States.

CX11 for Type 2 Diabetes

18 - 75
All Sexes
Birmingham, AL

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Phase 2
Waitlist Available

Central Research Associates - Flourish - PPDS (+29 Sites)

Corxel Pharmaceuticals

Have you considered Nesina clinical trials?

We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.
Go to Trials
Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA

People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.

Waitlist Available
Has No Placebo

KPNC Division of Research

Esti Iturralde, PhD

Have you considered Nesina clinical trials?

We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.
Go to Trials